Life Science Company News

Reset
Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Genomma Lab Internacional Announces Results for the First Quarter 2024

Read more ››
By: PR Newswire Association LLC. - 25 Apr 2024

Cytokinetics to Announce First Quarter Results on May 8, 2024

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Cytokinetics, Inc.

Madrigal Statement on the Passing of Dr. Stephen Harrison

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Madrigal Pharmaceuticals, Inc.

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Freeline Therapeutics Holdings plc | Freeline Therapeutics

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Kronos Bio, Inc.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Cidara Therapeutics, Inc.

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Iovance Biotherapeutics, Inc.

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Rhythm Pharmaceuticals, Inc.

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Intra-Cellular Therapies, Inc.

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Onco

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  FibroGen, Inc.

ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  ClearPoint Neuro, Inc.

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Cidara Therapeutics, Inc.

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Erasca, Inc.

Venus Concept Announces Loan Purchase and Completion of First Phase of Refinancing

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Venus Concept Inc.

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Black Diamond Therapeutics Inc.

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  23andMe, Inc.

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Corbus Pharmaceuticals Holdings, Inc.

Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Predictive Oncology Inc.

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  NextCure, Inc

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Read more ››
By: GlobeNewswire - 24 Apr 2024
Related companies:  Sensei Biotherapeutics, Inc.
Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Enhance your business development with Biotechgate
Try for free »